A Glimpse Into The Expert Outlook On Axsome Therapeutics Through 9 Analysts
Portfolio Pulse from Benzinga Insights
Nine analysts have recently published ratings on Axsome Therapeutics (NASDAQ:AXSM), with a mix of bullish and somewhat bullish sentiments. The average 12-month price target is $125.0, with a high of $190.00 and a low of $95.00. Financial challenges include a -20.7% decline in revenue, a net margin of -91.14%, and a high debt-to-equity ratio of 1.32.
August 05, 2024 | 5:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Axsome Therapeutics (NASDAQ:AXSM) has received mixed ratings from analysts, with an average 12-month price target of $125.0. The company faces financial challenges, including a -20.7% decline in revenue, a net margin of -91.14%, and a high debt-to-equity ratio of 1.32.
The mixed analyst ratings and financial challenges such as declining revenue and high debt-to-equity ratio suggest a neutral short-term impact on AXSM's stock price. While the average price target is slightly positive, the financial metrics indicate potential risks.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100